Vaxcyte, Inc.
$63.72-2.4%YTD+45.8%1Y+48.5%
Price updated 2m ago·X counts updated 5d ago
On X
The complete picture of $PCVX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
758X posts · last 7 days
Chatter Meter
0.9×
How loud $PCVX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $PCVX.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-9.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-40.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-11.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-37.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-1.97$-2.06+4.4%
Q1 2026May 6, 2026$-2.30$-1.78-29.4%
Q4 2025Feb 24, 2026$-1.80$-1.53-17.7%
Q3 2025Nov 4, 2025$-1.56$-1.27-22.8%
Next earningsTue, Nov 3·consensus EPS $-2.11
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-1.97$-532.5M
Q1 FY26$0———$-2.30$-295.4M
Q4 FY25$0———$-1.81$-219.3M
Q3 FY25$0———$-1.56$-155.4M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$25.0M$12.7M – $42.2M-$8.21-$9.73 – -$6.685
FY27$87.1M$87.1M – $87.1M-$6.52-$7.72 – -$5.379
FY28$177.1M$14.6M – $405.0M-$6.04-$11.07 – -$3.998
FY29$1.5B$757.8M – $2.5B$1.17$0.42 – $2.216
FY30$2.4B$1.2B – $4.1B$6.19$2.23 – $11.736
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.50%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KMaterial agreementOct 98-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 8.01: Other event
8-KPress release / Reg FDOct 58-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KOfficer or director changeSep 38-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 20 other (7 13Gs · 3 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a BetVaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock saleVaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company StockVaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesVaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days